P3–270: A 24‐week, open‐label extension to the ACTivities of daily living and cognitION (ACTION) study: Long‐term safety, tolerability and efficacy of a 13.3 mg/24 h rivastigmine patch in people with severe Alzheimer's disease. (1st July 2013) - Farlow, Martin; Grossberg, George; Sadowsky, Carl; Meng, Xiangyi; Somogyi, Monique